Lumateperone and Nitric Oxide Donor Combination for Resistant CNS Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved treatments for schizophrenia, depression, anxiety, and other central nervous system disorders, particularly in treatment-resistant patients, as existing therapies often have limited efficacy and side effects.
Innovation Solution
Combining a 5-HT2A or 5-HT2A/D2 receptor ligand, such as lumateperone, with a nitric oxide donor like sodium nitroprusside (SNP), either separately or in a fixed dose combination, to enhance therapeutic effects on psychosis, depression, and anxiety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antipsychotic and antidepressant therapies are used, then treatment coverage is provided, but efficacy is limited in treatment-resistant patients
Solution Approach 1:
The patent combines lumateperone (a 5-HT2A/D2 receptor ligand) with a nitric oxide donor (sodium nitroprusside) into a fixed-dose combination therapy. This merging of two distinct pharmacological agents with different mechanisms of action aims to overcome treatment resistance by simultaneously targeting multiple neurotransmitter systems (serotonin, dopamine, and nitric oxide pathways) that are implicated in psychosis and depression pathophysiology.
Solution Approach 2:
The invention creates a composite therapeutic regimen by formulating lumateperone and sodium nitroprusside together in a single pharmaceutical composition. This composite approach integrates the antipsychotic and antidepressant properties of lumateperone with the vasodilatory and neuromodulatory effects of nitric oxide donation, producing a synergistic effect that addresses both positive and negative symptoms of psychosis along with depressive features.
2Reliability
If combination therapy is used to improve efficacy, then therapeutic benefits are enhanced, but treatment complexity increases
Solution Approach 1:
The patent merges lumateperone and sodium nitroprusside into a single fixed-dose combination pharmaceutical composition, allowing both agents to be administered together in one dosage form. This eliminates the need for separate prescribing, dispensing, and administration of two different medications, thereby simplifying the treatment regimen while maintaining the synergistic therapeutic benefits of combination therapy.
Solution Approach 2:
The fixed-dose combination formulation serves multiple functions simultaneously: it provides antipsychotic coverage through lumateperone's 5-HT2A and D2 receptor activity, antidepressant effects through both agents, and simplified administration through a single dosage form. This multi-functional approach addresses various symptom domains (positive symptoms, negative symptoms, depression) while reducing treatment complexity.
3Reliability
If higher doses of single agents are used to overcome resistance, then efficacy may improve, but side effects increase
Solution Approach 1:
The patent employs parameter changes by utilizing sub-effective or low doses of lumateperone in combination with sodium nitroprusside, rather than using high doses of lumateperone alone. The nitric oxide donor component contributes to therapeutic efficacy through a different mechanism (cGMP pathway activation), allowing lumateperone to be used at lower doses that minimize dopaminergic side effects while the combination maintains overall treatment effectiveness through complementary mechanisms of action.
Data Source
AI summary
The disclosure provides methods for the for treatment of psychosis, such as schizophrenia, or depression (such as bipolar depression) and/or anxiety, comprising administering to a patient in need thereof, (i) a 5-HT2A or 5-HT2A/D2 receptor ligand, for example a substituted heterocycle fused gamma-carboline as described herein, in free, pharmaceutically acceptable salt or prodrug form, and (ii) a nitric oxide donor, separately (sequentially or simultaneously), or in combination (e.g., in a fixed dose combination).